anastrozole has been researched along with letrozole in 365 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (4.38) | 18.2507 |
| 2000's | 175 (47.95) | 29.6817 |
| 2010's | 146 (40.00) | 24.3611 |
| 2020's | 28 (7.67) | 2.80 |
| Authors | Studies |
|---|---|
| Belluti, F; Bertucci, C; Bisi, A; Cavalli, A; Giorgio, E; Gobbi, S; Hartmann, RW; Paluszcak, A; Piazzi, L; Rampa, A; Recanatini, M; Rosini, C; Valenti, P | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Hartmann, RW; Le Borgne, M; Lézé, MP; Palusczak, A | 1 |
| Acharya, KR; Chander, SK; Cozier, G; Jackson, T; Leonard, P; Potter, BV; Purohit, A; Putey, A; Reed, MJ; Woo, LW | 1 |
| Muftuoglu, Y; Mustata, G | 1 |
| Cushman, M; Kondratyuk, TP; Marler, L; Mayhoub, AS; Park, EJ; Pezzuto, JM | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Potter, BV; Thomas, MP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, JZ; Khan, MZI; Nazli, A; Uzair, M | 1 |
| Dowsett, M | 2 |
| Spencer, CM; Wiseman, LR | 1 |
| Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
| Harvey, HA | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W | 1 |
| Hamilton, A; Piccart, M | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Bonneterre, J; Feutrie, ML | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L | 1 |
| Smith, IE | 2 |
| Harvey, HA; Santen, RJ | 1 |
| Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
| Perey, L | 1 |
| Sonoo, H | 1 |
| Attolico, M; Crucitta, E; De Lena, M; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Dranitsaris, G; Leung, P; Mather, J; Oza, A | 1 |
| Buzdar, A | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Auvray, P; Bichat, F; Genne, P | 1 |
| de Crémoux, P | 1 |
| Kerbrat, P; Lefeuvre, C | 1 |
| Mokbel, K | 2 |
| Tominaga, T | 1 |
| Hamilton, A; Volm, M | 1 |
| Buzdar, A; Howell, A | 1 |
| Lønning, PE | 2 |
| Murray, R | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Bando, H; Saji, S; Toi, M | 1 |
| Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE | 1 |
| Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM | 1 |
| Dixon, JM; Miller, WR | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR | 1 |
| Buzdar, AU | 5 |
| Junker, A; Possinger, K; Wiedemann, GJ | 1 |
| Buzdar, A; Johnson, PE | 1 |
| Goss, PE | 1 |
| Bajetta, E; Bombardieri, E; Buzzoni, R; Catena, L; Celio, L; Ferrari, L; Gattinoni, L; La Torre, I; Martinetti, A; Pozzi, P; Seregni, E; Vitali, M; Zilembo, N | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Bajetta, E; Bichisao, E; Zilembo, N | 1 |
| Ingle, JN | 3 |
| Goss, PE; Smith, RE | 1 |
| Assikis, VJ; Buzdar, A | 1 |
| Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF | 1 |
| Robertson, JF | 1 |
| Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A | 1 |
| Dranitsaris, G; Trudeau, M; Verma, S | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Höffken, K; Sayer, HG | 1 |
| Baum, M; Buzdar, A | 1 |
| Rocchi, A; Verma, S | 1 |
| Rose, C | 2 |
| Brodie, AH; Mouridsen, HT | 1 |
| Thomas, R | 1 |
| Dixon, JM; Jackson, J; Miller, WR | 1 |
| Eckhardt, S | 1 |
| Lønning, P; Martoni, A; Pfister, C; Zamagni, C | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O | 1 |
| Dixon, JM; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Campos, SM | 1 |
| Arora, A; Potter, JF | 1 |
| Chaudri-Ross, HA; Mouridsen, HT | 1 |
| Al-Hadithi, N; Al-Omari, WR; Sulaiman, WR | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Howell, A; Tobias, JS | 1 |
| Tobias, JS | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK | 1 |
| Bloomfield, D; Godward, S; Makris, A; Moody, AM; Thomas, R; Williams, M | 1 |
| Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Harwood, KV | 1 |
| Fentiman, IS | 1 |
| Clemons, MJ; Freedman, OC; Verma, S | 1 |
| Mouridsen, HT | 2 |
| Kaplow, R | 1 |
| Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC | 1 |
| Geisler, J; Lønning, PE | 3 |
| Delozier, T; Khayat, D; Spano, JP | 1 |
| Dodwell, D; Vergote, I | 1 |
| Ingle, JN; Suman, VJ | 1 |
| Hamilton, AL; Nordman, IC; Spillane, AJ | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Gradishar, WJ | 1 |
| Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E | 1 |
| Chowdhury, S; Ellis, PA | 1 |
| Jiang, ZF; Song, ST | 1 |
| Chen, S; Itoh, T; Kijima, I | 1 |
| Mouridsen, HT; Robert, NJ | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Tuma, RS | 1 |
| Gltick, S | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Grana, G | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Ballester Navarro, I; Carrato Mena, A; Maciá Escalante, S; Pons Sanz, V; Rodríguez Lescure, A | 1 |
| Duffy, MJ | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP | 1 |
| Brueggemeier, RW | 1 |
| Goodwin, GM | 1 |
| Monnier, A | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K | 1 |
| Jonat, W; Mundhenke, C | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 1 |
| Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N | 1 |
| Kafy, S; Tulandi, T | 1 |
| Ashworth, A; Dexter, T; Dixon, JM; Dowsett, M; Drury, S; Evans, DB; Fenwick, K; Larionov, A; Mackay, A; Miller, WR; Urruticoechea, A; White, S; Young, O | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Badawy, A; Mosbah, A; Shady, M | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Cufer, T | 1 |
| Fabian, CJ | 1 |
| O'Shaughnessy, J | 1 |
| Perez, EA | 1 |
| Jahanzeb, M | 1 |
| Gurates, B; Kumru, S; Sandal, S; Yildiz, AA; Yilmaz, B | 1 |
| Clack, G; Eastell, R; Finkelman, RD; Fraser, WD; Hannon, RA; Lakner, G; McCloskey, EV; Miyamoto, A | 1 |
| Buxeraud, J; Chulia, AJ; Fagnere, C; Pouget, C; Yahiaoui, S | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Carpenter, R | 1 |
| Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Aapro, M | 1 |
| Cuzick, J | 1 |
| Pennery, E | 1 |
| A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O | 1 |
| Kihara, M; Miyauchi, A | 1 |
| Dixon, JM; Dowsett, M; Evans, DB; Murray, J; Renshaw, L; Thomas, JS; White, S; Williams, L; Young, OE | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Nagykálnai, T | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A | 1 |
| Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y | 1 |
| Abdelhady, H; Allam, AF; Badawy, A; Shokeir, T | 1 |
| Konje, JC; Verma, A | 1 |
| Brodie, A; Macedo, LF; Sabnis, G | 1 |
| Nothnick, WB; Zhang, X | 1 |
| Barker, LC; Brand, IR; Crawford, SM | 1 |
| Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K | 1 |
| Al-Sukhun, S; Chollet, P; Durando, X; Ferriere, JP; Mouret-Reynier, MA; Nabholtz, JM; Van Praagh, I | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Beiner, M; Ben-Baruch, G; Davidzon, T; Fridman, E; Korach, J; Perri, T | 1 |
| Bershteĭn, LM; Danilova, MA; Gershfel'd, ED; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Poroshina, TE; Tsyrlina, TE; Turkevich, EA | 1 |
| Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S | 1 |
| Glück, S | 1 |
| Barañao, RI; Bilotas, M; Meresman, G; Stella, I; Sueldo, C | 1 |
| Lazarus, P; Sun, D | 1 |
| Doyen, J; Ferrero, JM; Fontana, X; Italiano, A; Largillier, R; Thyss, A | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| El-Mardenly, G; Ezzat, Y; Gheita, TA; Hammam, W; Sayed, S | 1 |
| Badawy, AM; Dritsas, C; Mauri, D; Polyzos, NP; Tzioras, S; Valachis, A | 1 |
| Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nishiyama, K | 1 |
| Bastit, L; Briot, K; Kloos, I; Roux, C; Tubiana-Hulin, M | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Nothnick, WB | 2 |
| Devine, S; Sedjo, RL | 1 |
| Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Bertolini, E; Letho-Gyselinck, H; Prati, C; Wendling, D | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Eugster, EA; Fuqua, JS; Lenz, AM; Lewis, KA; Pescovitz, OH; Rahhal, S; Shulman, D | 1 |
| Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B | 1 |
| Delea, TE; Guo, A; Lipsitz, M | 1 |
| Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE | 1 |
| Tang, SC | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Doughty, JC | 1 |
| Geisler, J | 1 |
| Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA | 1 |
| Zhang, B | 1 |
| Landherr, L; Mészáros, E; Nagykálnai, T | 1 |
| Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B | 1 |
| Albertelli, MA; Feldman, D; Jensen, K; Krishnan, AV; Peng, L; Swami, S; Wang, JY | 1 |
| Ferrero, S; Gillott, DJ; Remorgida, V; Venturini, PL | 1 |
| Glück, S; Gorouhi, F | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Bershteĭn, LM; Boiarkina, MP; Danilova, MA; Gershfel'd, ÉD; Khadzhimba, AS; Kovalevskiĭ, AIu; Maksimov, SIa; Meshkova, IE; Turkevich, EA | 1 |
| Cao, MZ; Gu, L; He, PQ; Jiang, ZF; Li, B; Li, HY; Liu, GY; Liu, JP; Liu, YH; Lou, LH; Ma, LW; Shao, ZM; Shen, ZZ; Su, FX; Sun, SR; Tang, JH; Tang, LL; Wang, S; Wang, SM; Wang, X; Wang, XJ; Yu, KD; Zhang, HW; Zhang, QY; Zheng, H; Zhou, Y | 1 |
| Bakas, P; Creatsa, M; Creatsas, G; Gregoriou, O; Grigoriadis, C; Hassiakos, D | 1 |
| Katano, M; Kubo, M; Kuroki, S; Ogawa, T; Okido, M; Onishi, H; Shimada, K; Tanaka, M; Umeda, S; Yokohata, K | 1 |
| Allred, DC; Babiera, GV; Ballman, K; Bose, R; Chang, LW; Chen, K; Crowder, R; Demeter, R; DeSchryver, K; Ding, L; Dooling, DJ; Du, F; Elhammali, A; Ellis, MJ; Esserman, L; Fulton, LL; Fulton, RS; Goiffon, RJ; Goldstein, TC; Guenther, JM; Harris, CC; Harrison, M; Hoog, J; Hunt, K; Kandoth, C; Koboldt, DC; Leitch, M; Ley, TJ; Lin, L; Lu, C; Luo, J; Maher, CA; Marcom, PK; Mardis, ER; Margenthaler, J; McDonald, S; McLellan, MD; McMichael, JF; Miller, CA; Ng, S; Oberkfell, B; Olson, J; Ota, D; Piwnica-Worms, D; Piwnica-Worms, H; Schierding, WS; Shen, D; Snider, J; Stuart, JM; Suman, VJ; Tao, Y; Unzeitig, G; Van Tine, BA; Vickery, TL; Wallis, JW; Watson, M; Weber, J; Wendl, MC; Wilson, RK | 1 |
| Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS | 1 |
| A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Acar, H; Ata, O; Toy, H; Yavas, C; Yavas, G; Yuce, D | 1 |
| Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K | 1 |
| Aksoy, S; Altundag, K; Sendur, MA; Zengin, N | 1 |
| Bell, R; Bell, RJ; Chirgwin, J; Cicuttini, F; Davies-Tuck, M; Davis, SR; Hanna, F; Wang, Y | 1 |
| De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Tung, N | 1 |
| Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ | 1 |
| Akiyoshi, T; Asayama, T; Hiura, S; Kato, H; Masuda, S; Ohtani, H; Okamoto, Y; Shimomura, Y | 1 |
| Hosoya, T; Kusuhara, H; Miyajima, M; Sugiyama, Y; Takahashi, K; Takashima, T; Watanabe, Y | 1 |
| Bauer, M; Hadji, P; Hars, O; Kalder, M; Kyvernitakis, I; Ziller, V | 1 |
| Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J | 1 |
| Awang, K; Fadl-Elmula, I; Hasima, N; Idris, OF; In, LL; Ismail, AM; Mustafa, AH; Syamsir, DR; Tasyriq, M | 1 |
| Mehta, A; Tripathy, D | 1 |
| Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S | 1 |
| Akçay, HT; Bayrak, R | 1 |
| Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C | 1 |
| Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C | 1 |
| Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
| Dowsett, M; Haynes, BP; Lønning, PE | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Farquhar, C; Franik, S; Kremer, JA; Nelen, WL | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 2 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Arsav, V; Benderli Cihan, Y | 1 |
| Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M | 1 |
| Bowman, M; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Seluzicki, C; Xie, SX; Zee, J | 1 |
| Kumar, RB; Neely, EK; Payne, SL; Ranadive, SA; Suchet, DI | 1 |
| Olin, JL; St Pierre, M | 1 |
| Crocker, MK; Gourgari, E; Lodish, M; Stratakis, CA | 1 |
| Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M | 1 |
| Benemei, S; Coppi, E; De Logu, F; Di Tommaso, MR; Fusi, C; Geppetti, P; Marone, IM; Materazzi, S; Minocci, D; Moneti, G; Nassini, R; Pieraccini, G; Susini, T; Trevisan, G; Tuccinardi, T | 1 |
| Chatziralli, IP; Chrysikos, D; Ladas, I; Moschos, MM; Sergentanis, T; Zagouri, F; Zografos, G | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
| Bayer, J; Katzler, O; Mebes, I; Rune, G; Schultz, H; Sommer, T; Tobia, MJ | 1 |
| Biggers, A; Charlson, JA; Kamaraju, S; Laud, PW; Neuner, JM; Pezzin, LE; Smallwood, AJ; Smith, EC; Wozniak, EM | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Brodie, A; Guha, R; Jaiswal, AK; Khatri, R; Rassool, FV; Shah, P; Tomkinson, AE | 1 |
| Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Colleoni, M; Munzone, E | 1 |
| Dowsett, M; Yeo, B | 1 |
| Chen, JL; Jiang, B; Lou, HG; Ruan, ZR; Shao, R; Yu, LY | 1 |
| Harbeck, N | 1 |
| Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Agrogiannis, G; Boutas, I; Creatsas, G; Gregoriou, O; Kalampokas, T; Konstantopoulos, P; Korou, LM; Pergialiotis, V; Perrea, D; Salakos, N | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Bacci, M; Chiarugi, P; Dowsett, M; Fearns, A; Gao, Q; Giannoni, E; Isacke, CM; Martin, LA; Morandi, A; Pintus, G; Ribas, R; Taddei, ML | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Adlis, SA; Kirstein, MN; Lerner, RE; Liang, S; Richter, SA; Robien, K; Shapiro, AC | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S | 1 |
| Bjørkøy, G; Dixon, JM; Flågeng, MH; Geisler, J; Knappskog, S; Larionov, A; Lilleng, PK; Lønning, PE; Mellgren, G; Miller, WR; Prestvik, WS | 1 |
| Niraula, S; Ocana, A | 1 |
| Damaso, L; Gaete, X; Gagliardi, P; Hossain, J; Mauras, N; Mericq, V; Merinbaum, D; Permuy, J; Ross, JL; Singh, RJ; Yu, YM | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D | 1 |
| Brower, V | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Cohen, PR | 1 |
| Ellis, MJ; Goncalves, R; Reinert, T | 1 |
| Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG | 1 |
| Chen, T; Chu, F; Gong, Y; Lei, H; Liu, X; Lu, F; Xing, Y; Xu, B; Yan, M | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O | 1 |
| Vohora, D; Zameer, S | 1 |
| Deng, Y; Tian, W; Wu, M | 1 |
| Clayman, E; Huber, KM; Kumar, A; Smith, P | 1 |
| Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C | 1 |
| Dirix, LY | 1 |
| Bozkaya, Y; Demirci, NS; Erdem, GU | 1 |
| Eltrop, SM; Farquhar, C; Franik, S; Kiesel, L; Kremer, JA | 1 |
| Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J | 1 |
| Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM | 1 |
| Becherini, C; Bernini, M; Bianchi, S; Cecchini, S; De Feo, ML; Delli Paoli, C; Desideri, I; Francolini, G; Livi, L; Meattini, I; Nori, J; Orzalesi, L; Saieva, C; Salvestrini, V; Sanchez, L; Scotti, V; Visani, L | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
| Carpi, A; Ferrari, P; Morganti, R; Nicolini, A; Rossi, G | 1 |
| Jamal, QMS | 1 |
| Gui, L; Li, Q; Luo, Y; Sun, J; Wang, L; Wang, Q; Zhang, P; Zhang, S | 1 |
| Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E | 1 |
| Chen, C; Guan, J; Huang, X; Lin, Y; Mao, F; Shen, S; Sun, Q; Wang, C; Yao, R; Zhang, X; Zhao, J; Zhou, Y; Zhu, H | 1 |
| Adachi, K; Hirano, T; Sakurai, K; Suzuki, S | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Almeida, CF; Amaral, C; Augusto, TV; Correia-da-Silva, G; Teixeira, N | 1 |
| Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS | 1 |
| Li, P; Li, Z; Yang, C | 1 |
| Almås, B; Bertelsen, BE; Geisler, J; Hagland, M; Helland, T; Lende, TH; Lønning, PE; Mellgren, G; Sagen, JV; Søiland, H; Viste, K | 1 |
| Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB | 1 |
| Ng, BP; Park, C; Park, SK; Woo, A | 1 |
| Adamson, BJ; Bargo, D; Baxi, S; Briggs, A; Ghosh, S; Ramsey, S; Tan, K; Wang, X | 1 |
| Guo, B; Li, JJ; Liu, JG; Ma, YL; Zhao, YT | 1 |
| Elancheran, R; Maruthanila, VL; Mirunalini, S | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Acconcia, F | 1 |
| Boughey, JC; Ellis, MJ; Hunt, KK; Leitch, AM; Meric-Bernstam, F; Olson, J; Suman, VJ; Unzeitig, G; Wingate, HF | 1 |
| Deng, ZX; Li, YC; Shen, SJ; Sun, Q; Wang, YJ; Xu, T | 1 |
| Atia, AN; Darner, G; Hein, RE; Hollins, AW; Mithani, SK; Morris, M; Sergesketter, AR; Zhang, GX | 1 |
| Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC | 1 |
| Browning, A; Chekmenev, EY; Lehmkuhl, S; MacCulloch, K; Theis, T; TomHon, P | 1 |
| Bayaxi, N; Cheng, Y; Geng, C; Hu, C; Hu, X; Li, W; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wei, W; Wu, X; Xie, W; Xu, B; Xu, J; Yan, M; Yan, X; Zeng, X; Zhang, H; Zhang, P; Zhang, Q; Zhong, J; Zhu, X | 1 |
| Al Hussein Al Awamlh, B; Barocas, DA; Chang, SS; Cortese, BD; Dusetzina, SB; Luckenbaugh, AN; Penson, DF; Stimson, CJ; Talwar, R | 1 |
141 review(s) available for anastrozole and letrozole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen | 2022 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1997 |
Vorozole.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrogens; Fadrozole; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
[Preclinical evaluation of aromatase inhibitors antitumor activity].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Models, Animal; Nitriles; Rats; Structure-Activity Relationship; Triazoles | 2000 |
[Aromatase inhibitors: pharmacological aspects].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Survival Analysis; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Receptors, Estrogen; Treatment Outcome; Triazoles | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Premenopause; Triazoles | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Triazoles | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Humans; Letrozole; Molecular Structure; Nitriles; Triazoles | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Menopause; Nitriles; Triazoles | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
New advances in ovulation induction.
Topics: Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Letrozole; Nitriles; Receptor Cross-Talk; Transplantation, Heterologous; Trastuzumab; Triazoles | 2009 |
Future targets in endometriosis treatment: targeting the endometriotic implant.
Topics: Anastrozole; Angiogenesis Inhibitors; Animals; Aromatase Inhibitors; Clinical Trials as Topic; Endometriosis; Female; Humans; Letrozole; Molecular Structure; Nitriles; Triazoles | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cancer; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitors for female infertility: a systematic review of the literature.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Clomiphene; Female; Fertilization in Vitro; Gonadotropins; Humans; Infant, Newborn; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Triazoles | 2009 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Endometriosis: in search of optimal treatment.
Topics: Adalimumab; Anastrozole; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Endometriosis; Estrogen Receptor Modulators; Etanercept; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Letrozole; Nitriles; Pentoxifylline; Progesterone; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Triazoles; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP2D6; Female; Letrozole; Mice; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Triazoles | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Risk Factors; Triazoles | 2011 |
The emerging use of aromatase inhibitors for endometriosis treatment.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Disease Models, Animal; Endometriosis; Endometrium; Estrogens; Female; Fertility; Humans; Letrozole; Mice; Nitriles; Ovary; Pelvic Pain; Rats; Triazoles | 2011 |
Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review.
Topics: Anastrozole; Aromatase Inhibitors; Clinical Trials as Topic; Endometriosis; Female; Humans; Letrozole; Nitriles; Pain, Postoperative; Pelvic Pain; Triazoles | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Postmenopause; Survival Analysis; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Topics: Anastrozole; Aromatase Inhibitors; Birth Rate; Clomiphene; Coitus; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Randomized Controlled Trials as Topic; Triazoles | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Invasiveness; Nitriles; Postmenopause; Risk; Triazoles | 2014 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Hallucinations; Humans; Letrozole; Middle Aged | 2019 |
Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anastrozole; Aromatase Inhibitors; Birth Rate; Clomiphene; Coitus; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Live Birth; Nitriles; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Randomized Controlled Trials as Topic; Triazoles | 2018 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
Clinical application of aromatase inhibitors to treat male infertility.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Humans; Infertility, Male; Letrozole; Male; Semen Analysis | 2021 |
Efficacy and safety of letrozole or anastrozole in the treatment of male infertility with low testosterone-estradiol ratio: A meta-analysis and systematic review.
Topics: Anastrozole; Estradiol; Female; Follicle Stimulating Hormone; Humans; Infertility, Male; Letrozole; Male; Pregnancy; Semen; Sperm Motility; Testosterone | 2022 |
48 trial(s) available for anastrozole and letrozole
| Article | Year |
|---|---|
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Enzyme Inhibitors; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Triazoles | 2002 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2003 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Decision Making; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Postmenopause; Quality of Life; Single-Blind Method; Treatment Outcome; Triazoles | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment | 2004 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Nitriles; Oocytes; Ovulation Induction; Prospective Studies; Triazoles | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Research Design; Triazoles | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Polymerase Chain Reaction; Postmenopause; Receptors, Estrogen; Triazoles; Up-Regulation | 2007 |
RETRACTED: Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial.
Topics: Abortion, Spontaneous; Adult; Anastrozole; Aromatase Inhibitors; Clomiphene; Drug Resistance; Endometrium; Estradiol; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Nitriles; Ovarian Follicle; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Progesterone; Prospective Studies; Triazoles | 2008 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
Topics: Adrenal Glands; Alkaline Phosphatase; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Body Mass Index; Bone and Bones; Bone Remodeling; Bone Resorption; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Triazoles | 2007 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Progesterone; Treatment Outcome; Triazoles | 2009 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Triazoles | 2008 |
Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility.
Topics: Abortion, Spontaneous; Adult; Anastrozole; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Infant, Newborn; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Pregnancy; Pregnancy Outcome; Triazoles | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Triazoles | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Testosterone; Triazoles | 2011 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Patient Compliance; Physician-Patient Relations; Postmenopause; Practice Patterns, Physicians'; Prospective Studies; Surveys and Questionnaires; Triazoles | 2012 |
Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Estradiol; Hormones; Humans; Infertility, Male; Letrozole; Male; Nitriles; Organ Size; Semen Analysis; Testis; Testosterone; Triazoles | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Prednisolone; Triazoles | 2012 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hot Flashes; Humans; Letrozole; Medication Adherence; Middle Aged; Musculoskeletal Pain; Nitriles; Sleep Wake Disorders; Time Factors; Triazoles; Urinary Bladder Diseases; Vaginal Diseases | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Lymph Node Excision; Mastectomy; Medication Adherence; Middle Aged; Nitriles; Patient Education as Topic; Postmenopause; Triazoles | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depression; Electroacupuncture; Fatigue; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Sleep Wake Disorders; Stress, Psychological; Treatment Outcome; Triazoles | 2014 |
Letrozole vs anastrozole for height augmentation in short pubertal males: first year data.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Height; Child; Estradiol; Growth Disorders; Humans; Letrozole; Luteinizing Hormone; Male; Nitriles; Puberty; Testosterone; Treatment Outcome; Triazoles | 2014 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Letrozole; Middle Aged; Nerve Fibers; Nitriles; Optic Nerve; Retina; Tomography, Optical Coherence; Triazoles; Visual Acuity | 2016 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone Density; Breast Neoplasms; Cholecalciferol; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Nitriles; Triazoles; Vitamin D | 2016 |
Randomized Trial of Aromatase Inhibitors, Growth Hormone, or Combination in Pubertal Boys with Idiopathic, Short Stature.
Topics: Adolescent; Anastrozole; Aromatase Inhibitors; Body Composition; Body Height; Drug Therapy, Combination; Dwarfism; Growth Hormone; Humans; Letrozole; Male; Nitriles; Outcome Assessment, Health Care; Puberty; Triazoles | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Depression; Disease-Free Survival; Dyspnea; Female; Hot Flashes; Humans; Hypertension; Letrozole; Lymphatic Metastasis; Mastectomy; Middle Aged; Myalgia; Neoplasm Staging; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triazoles | 2017 |
Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population.
Topics: Aminoglutethimide; Anastrozole; Aromatase Inhibitors; Biomarkers, Pharmacological; Doping in Sports; Female; Hormones; Humans; Letrozole; Male; Models, Biological; Nitriles; Single-Blind Method; Steroids; Substance-Related Disorders; Triazoles; Young Adult | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Survival Rate; Treatment Outcome; Triazoles | 2017 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Letrozole; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Treatment Outcome | 2018 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ibandronic Acid; Letrozole; Middle Aged; Single-Blind Method | 2019 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Young Adult | 2020 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; Humans; Japan; Letrozole; Middle Aged; Progression-Free Survival; Quality of Life; Receptors, Progesterone | 2022 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant Therapy; Postmenopause; Receptors, Estrogen | 2023 |
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Receptor, ErbB-2; Treatment Outcome | 2023 |
177 other study(ies) available for anastrozole and letrozole
| Article | Year |
|---|---|
Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach.
Topics: Aromatase; Aromatase Inhibitors; Benzopyrans; Circular Dichroism; Drug Design; Humans; Ligands; Microsomes; Models, Molecular; Molecular Conformation; Placenta; Quantitative Structure-Activity Relationship; Spectrophotometry, Ultraviolet; Stereoisomerism; Steroid 17-alpha-Hydroxylase | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic; Hormones; Humans; Indoles; Inhibitory Concentration 50; Models, Chemical; Molecular Structure; Nitriles; Receptors, Estrogen; Steroid 17-alpha-Hydroxylase | 2008 |
Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template.
Topics: Animals; Aromatase Inhibitors; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Female; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Steryl-Sulfatase; Structure-Activity Relationship; Triazoles | 2010 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Simulation; Drug Design; Female; Humans; Models, Chemical; Models, Molecular; Structure-Activity Relationship | 2010 |
Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.
Topics: Aromatase; Aromatase Inhibitors; Binding Sites; Catalytic Domain; Computer Simulation; Enzyme Assays; Humans; Resveratrol; Stilbenes; Structure-Activity Relationship; Thiazoles | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosis; Estrone; Female; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steryl-Sulfatase; Sulfonic Acids; Tubulin Modulators | 2015 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 1997 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost Analysis; Decision Support Techniques; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogens; Estrone; Female; Fibroblasts; Humans; In Vitro Techniques; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Letrozole; Middle Aged; Nitriles; Postmenopause; Time Factors; Triazoles | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Research Design; Triazoles | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Middle Aged; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2004 |
Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Ovulation; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Triazoles | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female; Humans; Letrozole; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome; Triazoles | 2006 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Contraindications; Estrogens; Female; Humans; Letrozole; Mastectomy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Receptors, Estrogen; Triazoles | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Humans; Letrozole; Leuprolide; Lung Neoplasms; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Irritable Mood; Letrozole; Middle Aged; Nitriles; Substance Withdrawal Syndrome; Triazoles | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.
Topics: Amino Acids; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Dehydroepiandrosterone Sulfate; Dose-Response Relationship, Drug; Female; Letrozole; Nitriles; Osteocalcin; Rats; Testosterone; Triazoles | 2007 |
New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation.
Topics: Anastrozole; Aromatase Inhibitors; Benzene; Cyclization; Flavanones; Humans; Hydrogen Bonding; Letrozole; Microsomes; Molecular Structure; Nitriles; Structure-Activity Relationship; Triazoles | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Tomography, X-Ray Computed; Triazoles; Ultrasonography | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
Topics: Adult; Anastrozole; Aromatase Inhibitors; Chronic Disease; Dose-Response Relationship, Drug; Endometriosis; Estradiol; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Nitriles; Pelvic Pain; Premenopause; Treatment Outcome; Triazoles; Uterine Diseases | 2009 |
Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Carcinoma; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Organ Size; Retrospective Studies; Time Factors; Triazoles | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Promising effect of aromatase inhibitors on recurrent granulosa cell tumors.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Ovariectomy; Prognosis; Treatment Outcome; Triazoles | 2009 |
[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Chemotherapy, Adjuvant; Endometrial Neoplasms; Estradiol; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2010 |
Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
Topics: Anastrozole; Animals; Apoptosis; Aromatase; Aromatase Inhibitors; Ascitic Fluid; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Letrozole; Mice; Nitriles; Prostaglandins E; Triazoles; Vascular Endothelial Growth Factor A | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma; Estradiol; Humans; Letrozole; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Testosterone; Treatment Outcome; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Joint Diseases; Letrozole; Male; Middle Aged; Muscular Diseases; Neoplasms; Nitriles; Osteoporosis; Statistics, Nonparametric; Triazoles | 2010 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Retrospective Studies; Triazoles | 2009 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Databases as Topic; Delivery of Health Care; Drug Costs; Female; Health Knowledge, Attitudes, Practice; Humans; Insurance, Health; Letrozole; Logistic Models; Medication Adherence; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Triazoles; United States | 2011 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2011 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
Topics: Anastrozole; Androgen Antagonists; Anilides; Aromatase Inhibitors; Child, Preschool; Humans; Letrozole; Male; Nitriles; Puberty, Precocious; Testosterone; Tosyl Compounds; Triazoles | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit Analysis; Drug Substitution; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles; United Kingdom; United States | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Liver Neoplasms; Nitriles; Triazoles | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Calcitriol; Cell Line, Tumor; Cell Proliferation; Estrogens; Female; Humans; Immunohistochemistry; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Real-Time Polymerase Chain Reaction; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triazoles; Vitamins; Xenograft Model Antitumor Assays | 2011 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Endometrial Neoplasms; Female; Glucose; Humans; Hypoglycemic Agents; Ki-67 Antigen; Letrozole; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Nitriles; Treatment Outcome; Triazoles | 2011 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA Repair; Exome; Exons; Female; Genetic Variation; Genome, Human; Humans; Letrozole; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 1; Mutation; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Letrozole; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Retrospective Studies; Subtraction Technique; Triazoles | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2012 |
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Combined Modality Therapy; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Rats; Rats, Wistar; Statistics, Nonparametric; Tamoxifen; Triazoles | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blepharitis; Breast Neoplasms; Conjunctival Diseases; Dry Eye Syndromes; Female; Humans; Keratitis; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Retrospective Studies; Triazoles; Vision Disorders | 2013 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2012 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole; Magnetic Resonance Imaging; Menisci, Tibial; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Tibia; Triazoles | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States | 2013 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Diphosphonates; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Triazoles | 2013 |
Investigation of the effect of active efflux at the blood-brain barrier on the distribution of nonsteroidal aromatase inhibitors in the central nervous system.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Brain; Cell Line; Humans; Letrozole; Male; Mice; Nitriles; Triazoles | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Female; Humans; Letrozole; Middle Aged; Nitriles; Obesity; Postmenopause; Prospective Studies; Receptors, Estrogen; Survival Analysis; Triazoles | 2013 |
Extra virgin olive oil potentiates the effects of aromatase inhibitors via glutathione depletion in estrogen receptor-positive human breast cancer (MCF-7) cells.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Cytochromes c; Female; Glutathione; Humans; Letrozole; MCF-7 Cells; Nitriles; Oleic Acid; Olive Oil; Plant Oils; Reactive Oxygen Species; Receptors, Estrogen; Triazoles | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Computer Simulation; Female; Humans; Letrozole; Models, Molecular; Molecular Conformation; Nitriles; Proton Magnetic Resonance Spectroscopy; Static Electricity; Triazoles; Vibration | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden | 2014 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles | 2015 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Triazoles | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats.
Topics: Anastrozole; Androstadienes; Animals; Antibodies, Monoclonal; Aromatase Inhibitors; Combined Modality Therapy; Drug Administration Schedule; Female; Heart; Humans; Letrozole; Nitriles; Radiotherapy; Rats; Rats, Wistar; Trastuzumab; Triazoles; Tumor Protein, Translationally-Controlled 1 | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles | 2014 |
Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Topics: AMP-Activated Protein Kinase Kinases; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Development; Calcinosis; Carney Complex; Child; Child, Preschool; Growth; Gynecomastia; Humans; Infant; Letrozole; Male; Nitriles; Peutz-Jeghers Syndrome; Protein Serine-Threonine Kinases; Sertoli Cell Tumor; Treatment Outcome; Triazoles | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Everolimus; Female; Humans; Kazakhstan; Letrozole; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles | 2015 |
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1.
Topics: Anastrozole; Androstadienes; Animals; Aromatase Inhibitors; Behavior, Animal; Calcium; Calcium Channels; Cysteine; HEK293 Cells; Humans; Inflammation; Letrozole; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuropeptides; Nitriles; Pain; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Steroids; Transient Receptor Potential Channels; Triazoles; TRPA1 Cation Channel; TRPC Cation Channels | 2014 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |
The effect of estrogen synthesis inhibition on hippocampal memory.
Topics: Aged; Anastrozole; Estradiol; Female; Gyrus Cinguli; Hippocampus; Humans; Letrozole; Long-Term Potentiation; Longitudinal Studies; Magnetic Resonance Imaging; Memory; Memory, Short-Term; Middle Aged; Nitriles; Postmenopause; Prefrontal Cortex; Psychomotor Performance; Steroid Synthesis Inhibitors; Surveys and Questionnaires; Triazoles; Verbal Learning; Word Association Tests | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Costs; Drugs, Generic; Evaluation Studies as Topic; Female; Humans; Letrozole; Medicare; Medication Adherence; Nitriles; Non-Randomized Controlled Trials as Topic; Poverty; Triazoles; United States | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Letrozole; MCF-7 Cells; Molecular Structure; NF-E2-Related Factor 2; Nitriles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Triazoles; Ubiquitination | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles | 2015 |
Development and validation of a rapid LC-MS/MS method to quantify letrozole in human plasma and its application to therapeutic drug monitoring.
Topics: Anastrozole; Antineoplastic Agents; Chromatography, Liquid; Drug Monitoring; Humans; Letrozole; Limit of Detection; Nitriles; Tandem Mass Spectrometry; Triazoles | 2016 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Diarrhea; Disease Progression; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Retrospective Studies; Survival Rate; Triazoles | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.
Topics: Anastrozole; Animals; Female; Letrozole; Lipid Metabolism; Liver; Nitriles; Rats; Rats, Wistar; Triazoles | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Estrogens; Female; Glycolysis; Hexokinase; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Nude; MicroRNAs; Neoadjuvant Therapy; Nitriles; Phosphorylation; Receptors, Estrogen; Triazoles | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2016 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Schedule; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Letrozole; Mutation; Neuregulin-1; Nitriles; Receptor, ErbB-2; RNA, Messenger; Treatment Outcome; Triazoles | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Prognosis; Triazoles | 2017 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrogen; Tamoxifen | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
Effect of aromatase inhibitors on learning and memory and modulation of hippocampal dickkopf-1 and sclerostin in female mice.
Topics: Adaptor Proteins, Signal Transducing; Anastrozole; Androstadienes; Animals; Aromatase Inhibitors; Cognition; Female; Glycoproteins; Hippocampus; Intercellular Signaling Peptides and Proteins; Letrozole; Maze Learning; Memory; Mice; Nitriles; Triazoles; Wnt Signaling Pathway | 2017 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Female; Humans; Letrozole; Lipid Metabolism; Lipids; Middle Aged; Postmenopause; Retrospective Studies | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Incisional Hernia; Letrozole; Mammaplasty; Middle Aged; Myocutaneous Flap; Odds Ratio; Rectus Abdominis; Retrospective Studies; Risk Factors; Surgical Wound Infection; Tamoxifen; Treatment Outcome | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2018 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Immunotherapy; Letrozole; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Toremifene | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer Simulation; DNA Topoisomerases, Type II; Female; Humans; Letrozole; Protein Conformation | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole; Postmenopause; Prospective Studies | 2020 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Letrozole; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Withholding Treatment | 2020 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Local | 2020 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; Cyclins; Early Growth Response Protein 3; Estrogens; Female; Gene Expression Regulation, Neoplastic; Hormones; Humans; Letrozole; Receptors, Androgen; Receptors, Estrogen; Signal Transduction; Tumor Suppressor Proteins | 2021 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Nitriles; Postmenopause; Tandem Mass Spectrometry | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans; Letrozole; Male; Medicare; Quality of Life; Retrospective Studies; Tamoxifen; United States | 2022 |
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Humans; Letrozole; Middle Aged; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Rate | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catechin; Chlorogenic Acid; Cyclophosphamide; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Ligands; Molecular Docking Simulation; Paclitaxel; Quercetin; Tamoxifen; Trastuzumab | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
[A real-world study of the effects of endocrine therapy on liver function in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bilirubin; Breast Neoplasms; Female; Humans; Letrozole; Liver; Middle Aged; Retrospective Studies; Toremifene; Young Adult | 2023 |
Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer.
Topics: Adrenal Cortex Hormones; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incidence; Letrozole; Retrospective Studies; Steroids; Trigger Finger Disorder | 2023 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitriles; Tamoxifen; United States | 2023 |
Parahydrogen in Reversible Exchange Induces Long-Lived
Topics: Anastrozole; Antineoplastic Agents; Letrozole; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy | 2023 |
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Topics: Aged; Anastrozole; Cost Savings; Drug Costs; Drugs, Generic; Humans; Imatinib Mesylate; Letrozole; Medicare Part D; Prescription Drugs; Tamoxifen; United States | 2023 |